Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

ConclusionsKidney function impairment increased the AUC of roxadustat and its metabolites. TheCmax andt1/2 of roxadustat were comparable among groups. Roxadustat and its metabolites were not cleared by HD/HDF.Clinical Trials Registration Number:  NCT02965040.
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research